Streetbeat News

Stock Prices

FMC

Mizuho Securities analyst Edlain Rodriguez downgraded FMC Corp (NYSE:FMC) to Neutral from Buy, maintaining a price target of $59. The downgrade is attributed to expected earnings pressure in H2 FY23 due to a significant pesticide inventory correction and concerns about generic competition. Despite long-term opportunities, near-term uncertainties may affect investor confidence until management proves its ability to deliver. FMC's FY24 revenue outlook is $4.65 billion-$4.85 billion, with adjusted EBITDA of $1.025 billion-$1.125 billion, and free cash flow conversion over 100%. FMC shares are up 1.74% at $56.17.

Portfolio Pulse from Lekha Gupta

December 07, 2023 | 7:52 pm

TDC

Teradata's stock is trading lower after the company expressed a cautious outlook at a Barclays conference, indicating that a significant eight-figure deal is at risk of being delayed.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 7:51 pm

AMD

GFS

GSIT

MRVL

NXPI

SLAB

Semiconductor stocks are trading higher, potentially due to AMD's positive momentum after announcing its new AI chip. This news reflects strength in the sector and may influence other semiconductor companies.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 7:48 pm

STLA

Stellantis N.V. (NYSE: STLA) has entered into a partnership with Ample to integrate Ample's Modular Battery Swapping technology into Stellantis electric vehicles. The initial program will start in Madrid in 2024 with a fleet of 100 Fiat 500e's, aiming to reduce EV charging time and range anxiety. The technology will be tested within Stellantis' Free2move car sharing service, with plans to expand to other platforms and regions. Stellantis' Dare Forward 2030 strategic plan targets 100% BEV sales in Europe and 50% in the U.S. by 2030. STLA shares saw a slight increase of 0.3% to $22.57.

Portfolio Pulse from Shivani Kumaresan

December 07, 2023 | 7:39 pm

FRSX

Foresight Autonomous Holdings ADR (NASDAQ:FRSX) shares plummeted by 31.7% to $1.27 after announcing a registered direct offering of 4.5 million ADSs at $1.00 per ADS. The offering, which includes participation from the CEO, is expected to close around December 11 and aims to raise approximately $4.5 million before fees for general corporate purposes and working capital. FRSX's 52-week trading range is between $1.14 and $4.58.

Portfolio Pulse from Henry Khederian

December 07, 2023 | 7:32 pm

SPY

U.S. Treasury Secretary Janet Yellen has expressed confidence in the Federal Reserve's performance and the path of the U.S. economy, indicating a positive outlook despite recent challenges.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 7:31 pm

PWR

Quanta Services (NYSE:PWR) has delivered an average annual return of 17.12% over the past 15 years, outperforming the market by 5.57% on an annualized basis. A $1000 investment in PWR 15 years ago would be worth $11,455.14 today. The company's current market capitalization stands at $27.89 billion.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 7:30 pm

MPWR

Over the past 10 years, Monolithic Power Systems (NASDAQ:MPWR) has delivered an average annual return of 33.21%, outperforming the market by 23.34% on an annualized basis. A $1000 investment in MPWR a decade ago would be worth $17,215.82 today. Monolithic Power Systems currently has a market cap of $26.55 billion.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 7:30 pm

BNED

CIEN

CYN

PHIO

SVFD

TRKA

ZVSA

U.S. stocks saw gains with the Dow Jones rising by 100 points. Ciena Corp (CIEN) reported Q4 earnings that exceeded expectations with a 16% revenue increase to $1.129 billion and an adjusted EPS of $0.75. Save Foods (SVFD) shares surged 93% targeting the US carbon credit market. Cyngn (CYN) rose 88% on a new patent announcement. Barnes & Noble Education (BNED) gained 26% after positive earnings. Conversely, Troika Media Group (TRKA) plummeted 64% due to a Chapter 11 filing, ZyVersa Therapeutics (ZVSA) fell 35% after pricing a public offering, and Phio Pharmaceuticals (PHIO) dropped 41% following a warrant exercise.

Portfolio Pulse from Avi Kapoor

December 07, 2023 | 7:26 pm

PHIO

Phio Pharmaceuticals Corp's stock plummeted by 40% after the company announced the exercise of warrants for $2.8 million in gross proceeds at a reduced price of $1.33 per share. The warrants were originally issued at higher prices between 2018 and 2023. The funds raised are before fees and expenses, and the shares are from previously registered offerings under Form S-1 and Form S-3. PHIO's 52-week trading range is between $0.88 and $12.27.

Portfolio Pulse from Henry Khederian

December 07, 2023 | 7:25 pm